Promoted Content
Promoted Content

Find Ophthalmology Drugs in Phase III Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brolucizumab

            Therapeutic Area: Ophthalmology Product Name: Beovu

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 15, 2020

            Details:

            In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NCX 470

            Therapeutic Area: Ophthalmology Product Name: NCX 470

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: HBM Healthcare Investments

            Deal Size: $18.1 million Upfront Cash: Undisclosed

            Deal Type: Financing December 04, 2020